Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: A report from the Pediatric Brain Tumor Consortium (PBTC)

Gethin Williams, Frederic H. Fahey, S. Ted Treves, Mehmet Kocak, Ian F. Pollack, James M. Boyett, Larry E. Kun, Tina Young Poussaint

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: The rationale of this study was to investigate the feasibility of three-dimensional (3D) methods to analyze 18F-fluoro-deoxy-glucose (FDG) uptake in children with anaplastic astrocytoma (AA) in a multi-institutional trial, to compare 3D and two-dimensional (2D) methods and explore data associations with progression-free survival (PFS). Methods: 3D tumor volumes from pretreatment MR images (fluid attenuation inversion recovery and postgadolinium) of children with recurrent AA on a phase I trial of imatinib mesylate were coregistered to FDG positron emission tomography (PET) images. PET data were normalized. Four metrics were defined: the maximum ratio (maximum pixel value within the 3D tumor volume, normalized), the total ratio (cumulative pixel values within the tumor volume, normalized) and tumor mean ratio (total pixel value divided by volume, normalized). 2D analysis methods were compared. Cox proportional hazards models were used to estimate the association between these methods and PFS. Results: Strongest correlations between 2D and 3D methods were with analyses using postcontrast T1 images for volume of interest (VOI). The analyses suggest 3D maximum tumor and mean tumor ratios, whether normalized by gray matter or white matter, were associated with PFS. Conclusions: This study of a series of pretreatment AA patients suggests that 3D PET methods using VOIs based on postcontrast T1 correlate with 2D methods and are related to PFS. These methods yield an estimate of metabolically active tumor burden and may add prognostic information after tumor grade is determined. Future rigorous multi-institutional protocols with larger numbers of patients will be required for validation.

Original languageEnglish (US)
Pages (from-to)1651-1658
Number of pages8
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume35
Issue number9
DOIs
StatePublished - Sep 1 2008

Fingerprint

Astrocytoma
Brain Neoplasms
Positron-Emission Tomography
Pediatrics
Glucose
Tumor Burden
Disease-Free Survival
Neoplasms
Proportional Hazards Models

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma : A report from the Pediatric Brain Tumor Consortium (PBTC). / Williams, Gethin; Fahey, Frederic H.; Treves, S. Ted; Kocak, Mehmet; Pollack, Ian F.; Boyett, James M.; Kun, Larry E.; Poussaint, Tina Young.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, No. 9, 01.09.2008, p. 1651-1658.

Research output: Contribution to journalArticle

Williams, Gethin ; Fahey, Frederic H. ; Treves, S. Ted ; Kocak, Mehmet ; Pollack, Ian F. ; Boyett, James M. ; Kun, Larry E. ; Poussaint, Tina Young. / Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma : A report from the Pediatric Brain Tumor Consortium (PBTC). In: European Journal of Nuclear Medicine and Molecular Imaging. 2008 ; Vol. 35, No. 9. pp. 1651-1658.
@article{7eddff37cfcd40458d4b8c9f44c22aa0,
title = "Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma: A report from the Pediatric Brain Tumor Consortium (PBTC)",
abstract = "Purpose: The rationale of this study was to investigate the feasibility of three-dimensional (3D) methods to analyze 18F-fluoro-deoxy-glucose (FDG) uptake in children with anaplastic astrocytoma (AA) in a multi-institutional trial, to compare 3D and two-dimensional (2D) methods and explore data associations with progression-free survival (PFS). Methods: 3D tumor volumes from pretreatment MR images (fluid attenuation inversion recovery and postgadolinium) of children with recurrent AA on a phase I trial of imatinib mesylate were coregistered to FDG positron emission tomography (PET) images. PET data were normalized. Four metrics were defined: the maximum ratio (maximum pixel value within the 3D tumor volume, normalized), the total ratio (cumulative pixel values within the tumor volume, normalized) and tumor mean ratio (total pixel value divided by volume, normalized). 2D analysis methods were compared. Cox proportional hazards models were used to estimate the association between these methods and PFS. Results: Strongest correlations between 2D and 3D methods were with analyses using postcontrast T1 images for volume of interest (VOI). The analyses suggest 3D maximum tumor and mean tumor ratios, whether normalized by gray matter or white matter, were associated with PFS. Conclusions: This study of a series of pretreatment AA patients suggests that 3D PET methods using VOIs based on postcontrast T1 correlate with 2D methods and are related to PFS. These methods yield an estimate of metabolically active tumor burden and may add prognostic information after tumor grade is determined. Future rigorous multi-institutional protocols with larger numbers of patients will be required for validation.",
author = "Gethin Williams and Fahey, {Frederic H.} and Treves, {S. Ted} and Mehmet Kocak and Pollack, {Ian F.} and Boyett, {James M.} and Kun, {Larry E.} and Poussaint, {Tina Young}",
year = "2008",
month = "9",
day = "1",
doi = "10.1007/s00259-008-0780-7",
language = "English (US)",
volume = "35",
pages = "1651--1658",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Exploratory evaluation of two-dimensional and three-dimensional methods of FDG PET quantification in pediatric anaplastic astrocytoma

T2 - A report from the Pediatric Brain Tumor Consortium (PBTC)

AU - Williams, Gethin

AU - Fahey, Frederic H.

AU - Treves, S. Ted

AU - Kocak, Mehmet

AU - Pollack, Ian F.

AU - Boyett, James M.

AU - Kun, Larry E.

AU - Poussaint, Tina Young

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Purpose: The rationale of this study was to investigate the feasibility of three-dimensional (3D) methods to analyze 18F-fluoro-deoxy-glucose (FDG) uptake in children with anaplastic astrocytoma (AA) in a multi-institutional trial, to compare 3D and two-dimensional (2D) methods and explore data associations with progression-free survival (PFS). Methods: 3D tumor volumes from pretreatment MR images (fluid attenuation inversion recovery and postgadolinium) of children with recurrent AA on a phase I trial of imatinib mesylate were coregistered to FDG positron emission tomography (PET) images. PET data were normalized. Four metrics were defined: the maximum ratio (maximum pixel value within the 3D tumor volume, normalized), the total ratio (cumulative pixel values within the tumor volume, normalized) and tumor mean ratio (total pixel value divided by volume, normalized). 2D analysis methods were compared. Cox proportional hazards models were used to estimate the association between these methods and PFS. Results: Strongest correlations between 2D and 3D methods were with analyses using postcontrast T1 images for volume of interest (VOI). The analyses suggest 3D maximum tumor and mean tumor ratios, whether normalized by gray matter or white matter, were associated with PFS. Conclusions: This study of a series of pretreatment AA patients suggests that 3D PET methods using VOIs based on postcontrast T1 correlate with 2D methods and are related to PFS. These methods yield an estimate of metabolically active tumor burden and may add prognostic information after tumor grade is determined. Future rigorous multi-institutional protocols with larger numbers of patients will be required for validation.

AB - Purpose: The rationale of this study was to investigate the feasibility of three-dimensional (3D) methods to analyze 18F-fluoro-deoxy-glucose (FDG) uptake in children with anaplastic astrocytoma (AA) in a multi-institutional trial, to compare 3D and two-dimensional (2D) methods and explore data associations with progression-free survival (PFS). Methods: 3D tumor volumes from pretreatment MR images (fluid attenuation inversion recovery and postgadolinium) of children with recurrent AA on a phase I trial of imatinib mesylate were coregistered to FDG positron emission tomography (PET) images. PET data were normalized. Four metrics were defined: the maximum ratio (maximum pixel value within the 3D tumor volume, normalized), the total ratio (cumulative pixel values within the tumor volume, normalized) and tumor mean ratio (total pixel value divided by volume, normalized). 2D analysis methods were compared. Cox proportional hazards models were used to estimate the association between these methods and PFS. Results: Strongest correlations between 2D and 3D methods were with analyses using postcontrast T1 images for volume of interest (VOI). The analyses suggest 3D maximum tumor and mean tumor ratios, whether normalized by gray matter or white matter, were associated with PFS. Conclusions: This study of a series of pretreatment AA patients suggests that 3D PET methods using VOIs based on postcontrast T1 correlate with 2D methods and are related to PFS. These methods yield an estimate of metabolically active tumor burden and may add prognostic information after tumor grade is determined. Future rigorous multi-institutional protocols with larger numbers of patients will be required for validation.

UR - http://www.scopus.com/inward/record.url?scp=50449091046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50449091046&partnerID=8YFLogxK

U2 - 10.1007/s00259-008-0780-7

DO - 10.1007/s00259-008-0780-7

M3 - Article

C2 - 18425516

AN - SCOPUS:50449091046

VL - 35

SP - 1651

EP - 1658

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 9

ER -